Document is current

Article History

Received: 25 November 2020

Revised: 30 December 2020

Accepted: 3 February 2021

First Online: 15 February 2021

Declarations

:

: The scientific guarantor of this publication is Alessandro Furlan.

: The authors of this manuscript declare relationships with the following companies:Tyler J. Fraum: consultant for Arterys; research support from Siemens.Amir A. Borhani: consultant for Guebert; book contract from Elsevier/Amirsys.Alessandro Furlan: consultant for Bracco; royalties from Elsevier.

: One of the authors (Tyler J. Fraum) has significant statistical expertise.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained.

: We would like to specify that, given to the 10-year inclusion period, eligible patients selected for this study in both participating Institutions were also included in prior studies (Title 1: Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018 [<i>n</i> = 178] – Title 2: Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria [<i>n</i> = 131] – Title 3: Assessment of Primary Liver Carcinomas other than Hepatocellular Carcinoma (HCC) with LI-RADS v2018: Comparison of the LI-RADS Target Population to Patients without LI-RADS-defined HCC Risk Factors [n = 265]) not related to this investigation. However, for this study, all the patients were re-reviewed in a blinded fashion by authors not involved in prior imaging assessment.

: • retrospective• diagnostic or prognostic study• multicenter study